Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI and Safety of BR3006-1, BR3006-2, and BR3006-3 in Healthy Volunteers
NCT05951946Phase 1Completed
- Sponsor
- Boryung
- Start
- Jul 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin, pioglitazone and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Boryung. Primary endpoints: Area Under the Concentration-time Curve at Steady State at Day 10 and Maximum Plasma Concentration at Steady State at Day 10. Started Jul 2023; status: completed.
02
Drugs
dapagliflozinpioglitazoneliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05951946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05951946.